Clinical trials have shown that nivolumab has remarkable activity against relapsed/refractory classical Hodgkin lymphoma (cHL). However, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation therapy in these patients remains controversial. We performed a retrospective analysis of data from 74 patients treated with nivolumab. The overall response rate was 58% (including 30.6% with complete responses). Treatment-related adverse events were reported in 56.8% of patients (grade ≥3 in 9.4%). The main reasons for nivolumab discontinuation were referral for transplantation (41.7% patients) and disease progression (37.5%). The 2-year overall survival (OS) rate was 52% for the entire series. Ultimately, 39 patients underwent allo-HSCT. The cumulative incidence of grade II-IV acute graft-versus-host disease was 33.3% (grade III-IV in 2 patients). The cumulative incidence of nonrelapse mortality was 13.2%. Among the patients who responded to nivolumab, the 2-year OS and progression-free survival (PFS) were higher in patients who underwent consolidation with allo-HSCT (77.5% versus 42.6% [P = .126] and 73.9% versus 27.2% [P = .025], respectively). Thus, the efficacy and safety of nivolumab were comparable to values reported in previous clinical trials. The percentage of patients who bridged to transplantation was high, indicating a preference for Spanish physicians. These results suggest that consolidation allo-HSCT increases OS and PFS.

临床试验表明，nivolumab对复发/难治性经典霍奇金淋巴瘤（cHL）具有显着活性。然而，异基因造血干细胞移植（allo-HSCT）作为巩固治疗在这些患者中的作用仍存在争议。我们对74例接受nivolumab治疗的患者的数据进行了回顾性分析。总体回应率为58％（包括完整回应的30.6％）。据报告有56.8％的患者与治疗相关的不良事件（9.4％≥3级）。尼古鲁单抗停药的主要原因是转诊移植（41.7％患者）和疾病进展（37.5％）。整个系列的2年总生存率（OS）为52％。最终，对39例患者进行了all-HSCT。II-IV级急性移植物抗宿主病的累积发生率是33。3％（2例患者为III-IV级）。非复发死亡率的累积发生率为13.2％。在对纳武单抗有反应的患者中，接受异体-HSCT巩固治疗的患者的2年OS和无进展生存期（PFS）更高（分别为77.5％和42.6％[P = .126]和73.9％对27.2％[ P = .025]。因此，nivolumab的疗效和安全性与先前临床试验中报道的值相当。接受移植的患者比例很高，这表明他们更喜欢西班牙医生。这些结果表明，整合allo-HSCT可增加OS和PFS。